Reg FD Disclosure

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     FORM 8-K     CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report:  December 10, 2020 (Date of earliest event reported)     BIO-RAD LABORATORIES, INC. (Exact name of registrant as specified in its charter)     Commission File Number: 1-7928   Delaware   94-1381833 (State or other jurisdiction of incorporation or organization)   (I.R.S. Employer Identification No.) 1000 Alfred Nobel Dr. Hercules , California 94547 (Address of principal executive offices, including zip code) (510) 724-7000 (Registrant’s telephone number, including area code)     Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:   ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)   ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)   ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))   ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:   Title of each class   Trading Symbol(s)   Name of each exchange on which registered Class A Common Stock, Par Value $0.0001 per share   BIO   New York Stock Exchange Class B Common Stock, Par Value $0.0001 per share   BIOb   New York Stock Exchange Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company   ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐       ITEM 7.01 Regulation FD Disclosure. On December 10, 2020, Bio-Rad Laboratories, Inc. (the “Company”) posted an investor presentation to its website at https://www.bio-rad.com/en-us/corporate/investor-relations and issued a press release relating to the investor presentation. A copy of the investor presentation is attached as Exhibit 99.1 to this Current Report on Form 8-K, and a copy of the press release is attached as Exhibit 99.2 to this Current Report on Form 8-K The information contained in Item 7.01 of this Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.   ITEM 9.01 Financial Statements and Exhibits (d) Exhibits   Exhibit Number    Description 99.1    Investor Presentation of Bio-Rad Laboratories, Inc. dated December 10, 2020 99.2    Press Release of Bio-Rad Laboratories, Inc. dated December 10, 2020 104    Cover Page Interactive Data File - the cover page iXBRL tags are embedded within the Inline XBRL document SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.       BIO-RAD LABORATORIES, INC. Date: December 10, 2020     By:   /s/ Ilan Daskal       Ilan Daskal       Executive Vice President and Chief Financial Officer